Erratum to: Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization (British Journal of Haematology, (2015), 170, 6, (874-883), 10.1111/bjh.13512);Synergistic intracellular iron chelation combinations: Mechanisms and conditions for optimizing iron mobilization

British Journal of Haematology

Volumn 170, Issue 6, 2015, Pages 874-883

  Vlachodimitropoulou Koumoutsea, Evangelia ^a   Garbowski, Maciej ^a   Porter, John ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Combination chelation therapy; Iron chelation; Iron overload; Isobologram; Thalassaemia

Indexed keywords

1 [ETHAN 1' OL] 2 METHYL 3 HYDROXYPYRIDIN 4 ONE; CHELATING AGENT; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; HYDROXYPYRIDINONE; IRON CHELATING AGENT; UNCLASSIFIED DRUG; 1-(ETHAN-1-OL)-2-METHYL-3-HYDROXYPYRIDIN-4-ONE; BENZOIC ACID DERIVATIVE; IRON; PYRIDONE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANALYTICAL PARAMETERS; ARTICLE; CELL ASSAY; CELL VIABILITY; COMBINATION CHEMOTHERAPY; COMBINATION INDEX; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE REDUCTION INDEX; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; FERROZINE ASSAY; HUH 7 CELL LINE; HUMAN; HUMAN CELL; INCUBATION TIME; INTRACELLULAR IRON CHELATION; IRON CHELATION; IRON KINETICS; LIPID SIZE; LIPID SOLUBILITY; LIVER CELL; MATHEMATICAL ISOBOLOGRAM; MATHEMATICAL MODEL; MATHEMATICAL PHENOMENA; MOLECULAR WEIGHT; MONOTHERAPY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SURFACE CHARGE; SYNERGY INDEX ALPHA; TIME SERIES ANALYSIS; CELL LINE; CHEMISTRY; INTRACELLULAR SPACE; METABOLISM;

BENZOATES; CELL LINE; DEFEROXAMINE; DRUG SYNERGISM; HUMANS; INTRACELLULAR SPACE; IRON; IRON CHELATING AGENTS; PYRIDONES; TRIAZOLES;

EID: 84940597487     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.16989     Document Type: Erratum

References (36)

1. Alderigh, L., Gans, P., Ienco, A., Peters, D., Sabatini, A. & Vacca, A. (1999) Hyperquad simulation and speciation (HySS): a utility program for the investigation of equilibria involving soluble and partially soluble species. Coordination Chemistry Reviews, 184, 311-318.
2. Aydinok, Y., Ulger, Z., Nart, D., Terzi, A., Cetiner, N., Ellis, G., Zimmermann, A. & Manz, C. (2007) A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica, 92, 1599-1606.
3. Aydinok, Y., Evans, P., Manz, C.Y. & Porter, J.B. (2012) Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response. Haematologica, 97, 835-841.
4. Aydinok, Y., Kattamis, A., Domenica Cappellini, M., El-Beshlawy, A., Origa, R., Elalfy, M., Kilinç, Y., Perrotta, S., Karakas, Z., Viprakasit, V., Habr, D., Wegener, A, Shen, J. & Porter, J.B. (2013) Deferasirox-deferoxamine combination therapy reduces cardiac iron with rapid liver iron removal in patients with severe transfusional iron overload (HYPERION). Blood (ASH Annual Meeting Abstracts), 122, 2257.
5. Cooper, C.E., Lynagh, G.R., Hoyes, K.P., Hider, R.C., Cammack, R. & Porter, J.B. (1996) The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. The Journal of Biological Chemistry, 271, 20291-20299.
6. Dobbin, P.S., Hider, R.C., Hall, A.D., Taylor, P.D., Sarpong, P., Porter, J.B., Xiao, G. & van der Helm, D. (1993) Synthesis, physicochemical properties, and biological evaluation of N- substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential. Journal of Medicinal Chemistry, 36, 2448-2458.
7. Elalfy, M., Wali, Y., Tony, S., Samir, A. & Adly, A. (2013) Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with ß-thalassemia major. Blood (ASH Annual Meeting Abstracts), 122, 559.
8. Evans, P., Kayyali, R., Hider, R.C., Eccleston, J. & Porter, J.B. (2010) Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. Translational Research: The Journal of Laboratory and Clinical Medicine, 156, 55-67.
9. Galanello, R., Piga, A., Forni, G.L., Bertrand, Y., Foschini, M.L., Bordone, E., Leoni, G., Lavagetto, A., Zappu, A., Longo, F., Maseruka, H., Hewson, N., Sechaud, R., Belleli, R. & Alberti, D. (2006) Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica, 91, 1343-1351.
10. Glickstein, H., El, R.B., Shvartsman, M. & Cabantchik, Z.I. (2005) Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood, 106, 3242-3250.
11. Glickstein, H., El, R.B., Link, G., Breuer, W., Konijn, A.M., Hershko, C., Nick, H. & Cabantchik, Z.I. (2006) Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood, 108, 3195-3203.
12. Grabovsky, Y. & Tallarida, R.J. (2004) Isobolographic analysis for combinations of a full and partial agonist: curved isoboles. The Journal of Pharmacology and Experimental Therapeutics, 310, 981-986.
13. Grady, R. & Giardina, P. (2000) Iron Chelation: Rationale for Combination Therapy. The Saratoga Group, Ponte Verde Beach, FL.
14. Hoyes, K.P. & Porter, J.B. (1993) Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools. British Journal of Haematology, 85, 393-400.
15. Ihnat, P., Vennerstrom, J. & Robinson, D. (2002) Solution equilibria of deferoxamine amides. Journal of Pharmaceutical Sciences, 91, 17733-41.
16. Jirasomprasert, T., Morales, N.P., Limenta, L.M., Sirijaroonwong, S., Yamanont, P., Wilairat, P., Fucharoen, S. & Chantharaksri, U. (2009) Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in beta-thalassemia. Free Radical Research, 43, 485-491.
17. Lal, A., Porter, J., Sweeters, N., Ng, V., Evans, P., Neumayr, L., Kurio, G., Harmatz, P. & Vichinsky, E. (2013) Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells, Molecules & Diseases, 50, 99-104.
18. Limenta, L.M., Jirasomprasert, T., Jittangprasert, P., Wilairat, P., Yamanont, P., Chantharaksri, U., Fucharoen, S. & Morales, N.P. (2011) Pharmacokinetics of deferiprone in patients with beta-thalassaemia: impact of splenectomy and iron status. Clinical Pharmacokinetics, 50, 41-50.
19. Link, G., Ponka, P., Konijn, A.M., Breuer, W., Cabantchik, Z.I. & Hershko, C. (2003) Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells. Blood, 101, 4172-4179.
20. Martell, A. (1981) The Design and Synthesis of Chelating Agents. Elsevier North Holland Inc., Development of iron chelators for clinical use. pp 67-104. Elsevier/North-Holland, Amsterdam. 1981
21. Morales, N.P., Yamanont, P., Jirasomprasert, T., Wilairat, P., Chantharaksri, U., Chuncharunee, S. & Fucharoen, S. (2009) Bioequivalence study of a film-coated tablet of deferiprone in healthy Thai volunteers. International Journal of Clinical Pharmacology and Therapeutics, 47, 358-364.
22. Motekaitis, R. & Martell, A. (1991) Stabilities of the iron(III) chelates of 1, 2-dimethyl-3-hydroxy-4-pyridinone and related ligands. Inorganica Chimica Acta, 183, 71-80.
23. Nakabayashi, H., Taketa, K., Miyano, K., Yamane, T. & Sato, J. (1982) Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Research, 42, 3858-3863.
24. Nick, H., Wong, A., Acklin, P., Faller, B., Jin, Y., Lattmann, R., Sergejew, T., Hauffe, S., Thomas, H. & Schnebli, H.P. (2002) ICL670A: preclinical profile. Advances in Experimental Medicine and Biology, 509, 185-203.
25. Piga, A., Galanello, R., Forni, G.L., Cappellini, M.D., Origa, R., Zappu, A., Donato, G., Bordone, E., Lavagetto, A., Zanaboni, L., Sechaud, R., Hewson, N., Ford, J.M., Opitz, H. & Alberti, D. (2006) Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica, 91, 873-880.
26. Porter, J. & Hershko, C. (2012) The properties of clinically useful iron chelators. In: Iron Physiology and Pathophysiology in Humans (ed. by H.J. Anderson & G.D. McLaren), Chapter 28, pp. 591-630. Humana Press (Book), Iron physiology and pathophysiology in humans.
27. Porter, J.B., Gyparaki, M., Burke, L.C., Huehns, E.R., Sarpong, P., Saez, V. & Hider, R.C. (1988) Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant. Blood, 72, 1497-1503.
28. Porter, J.B., Morgan, J., Hoyes, K.P., Burke, L.C., Huehns, E.R. & Hider, R.C. (1990) Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice. Blood, 76, 2389-2396.
29. Porter, J.B., Rafique, R., Srichairatanakool, S., Davis, B.A., Shah, F.T., Hair, T. & Evans, P. (2005) Recent insights into interactions of deferoxamine with cellular and plasma iron pools: implications for clinical use. Annals of the New York Academy of Sciences, 1054, 155-168.
30. Porter, J.B., Wood, J., Olivieri, N., Vichinsky, E.P., Taher, A., Neufeld, E., Giardina, P., Thompson, A., Moore, B., Evans, P., Kim, H.Y., Macklin, E.A. & Trachtenberg, F. (2013) Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. Journal of Cardiovascular Magnetic Resonance, 15, 38.
31. Riemer, J., Hoepken, H.H., Czerwinska, H., Robinson, S.R. & Dringen, R. (2004) Colorimetric ferrozine-based assay for the quantitation of iron in cultured cells. Analytical Biochemistry, 331, 370-375.
32. Srichairatanakool, S., Kemp, P. & Porter, J.B. (1997) Evidence for "shuttle" effect of NTBI onto desferrioxamine in thalassaemic plasma in the presence of NTA. In: International Symposium: Iron in Biology and Medicine, p. 210 (abstract), St. Malo, France.
33. Tallarida, R.J. (2001) Drug synergism: its detection and applications. The Journal of Pharmacology and Experimental Therapeutics, 298, 865-872.
34. Tallarida, R.J. (2006) An overview of drug combination analysis with isobolograms. The Journal of Pharmacology and Experimental Therapeutics, 319, 1-7.
35. Tanner, M.A., Galanello, R., Dessi, C., Smith, G.C., Westwood, M.A., Agus, A., Roughton, M., Assomull, R., Nair, S.V., Walker, J.M. & Pennell, D.J. (2007) A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation, 115, 1876-1884.
36. Waldmeier, F., Bruin, G.J., Glaenzel, U., Hazell, K., Sechaud, R., Warrington, S. & Porter, J.B. (2010) Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 38, 808-816.